Evofem shareholders reject merger with Aditxt; merger terminated

Evofem Biosciences, Inc.

Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.
Evofem terminates Merger Agreement with Aditxt effective Oct 20, 2025; no termination fee paid.
Company pivots to seek national stock listing and growth capital, targeting sustainable positive EBITDA in 2027.
CEO states collaboration with Aditxt for Mitomic diagnostic tests continues under September 2024 agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.